Investment

Sanofi Says Drug Shows Potential to Slow Diabetes in Late-Stage Trial

1 Mins read

By Adria Calatayud


Sanofi said its Tzield drug met the primary goal of a phase 3 clinical trial, showing potential to slow the progression of a type of diabetes in newly diagnosed children and adolescents.

The French pharmaceutical giant said Tzield demonstrated in the trial superior beta-cell preservation compared with placebo, and that this indicates its potential to slow the progression of Stage 3 type 1 diabetes in this population.

The trial studied the efficacy and safety of the drug in children and adolescents aged 8-17 years, the company said.

Results for the study’s key secondary goals, which included a numerically lower mean insulin dose, weren’t considered statistically significant, Sanofi said.

Sanofi added Tzield to its portfolio through the acquisition of Provention Bio, which was completed in April.


Write to Adria Calatayud at [email protected]


Read the full article here

Related posts
Investment

Opinion: The top 10% of Americans are propping up the economy. Here’s what will happen if they stop spending. 

1 Mins read
Outside the Box The wealthy are spending, but many consumers are pulling back — and the stock market is fragile Last Updated:…
Investment

AMC’s most liquid bond is rallying following the movie-theater chain’s fourth-quarter results

1 Mins read
Published: Feb. 27, 2025 at 1:23 p.m. ET AMC Entertainment Holdings Inc.’s most liquid bond rallied this week, lifted by better-than-expected fourth-quarter revenue…
Investment

Okta delivers what some of its bigger peers couldn’t: a rosy outlook

1 Mins read
Last Updated: March 3, 2025 at 8:14 p.m. ETFirst Published: March 3, 2025 at 4:38 p.m. ET Not all software companies are giving upbeat…
Get The Latest News

Subscribe to get the top fintech and
finance news and updates.

Leave a Reply

Your email address will not be published. Required fields are marked *